The United States Agency for International Development (USAID), on behalf of the American people, has donated to the Ministry of Public Health 4,800 doses of an important medicine used to treat people with severe cases of COVID-19.
This medicine, valued at 144,000,000 Ariary ($36,000 USD) is used to prevent and treat blood clots (thrombosis) that can block the normal circulation of blood, a condition that is common in severe cases of COVID-19.
“Since the early days of the pandemic, the United States has supported COVID-19 response efforts in Madagascar and we will continue to do so,” said Sophia Brewer, Director of USAID Madagascar’s health office.
“The U.S. government and the Government of Madagascar are like ‘Mpirahalahy mianala’ in responding to COVID-19 in Madagascar. We are steadfastly committed to strengthening Madagascar’s capacity to prevent, detect, and respond to the coronavirus disease,” said Director Brewer.
The Ministry of Public Health’s Secretary General and Director General in charge of Health Care Supplies received this life-saving medication from USAID’S IMPACT health project, which PSI Madagascar operates.
This is USAID’s latest donation in a series of efforts to augment Madagascar’s response to COVID-19 and treat people who have fallen ill with the disease. Previous USAID donations include a generator to the Boeny Regional Public Health Directorate to ensure the safe storage of vaccines; water containers and sanitation supplies for COVID-19 Treatment Centers in Antananarivo; and disinfectant products and personal protective equipment for various regional public health offices.
Since March 2020, the U.S. government has provided Madagascar with assistance valued at more than 51 billion Ariary ($13 million USD) to support the fight against COVID-19.
USAID’s IMPACT project is building up Madagascar’s supply chain for health products, specifically in the areas of maternal and child health, malaria control, and family planning. When the COVID-19 pandemic began, USAID expanded the role of the IMPACT project to include providing vaccines, medicine, supplies, and equipment for the treatment and prevention of COVID-19. The project also supports COVID-19 awareness raising activities, and data collection and sharing.
Through USAID, the U.S. government is supporting the delivery and rollout of vaccines, expanding infectious disease testing, providing protective equipment and training for Madagascar’s health workers, raising awareness about healthy behaviors, and upgrading and expanding laboratories. In addition, the United States is the largest donor of COVID-19 vaccines to Madagascar and the largest donor to COVAX worldwide.
Distributed by APO Group on behalf of U.S. Embassy in Madagascar&Comoros.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
